Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyruvate kinase thermal stability in hereditary hemolytic anemias
NL-OMON55777Recruiting
- Sponsor
- Agios Pharmaceuticals
- Start
- Dec 2017
- Countries
- 1
01
Overview
Open-label trial in hemoglobinopathies, sickle cell disease (SCD), beta thalassemia and 1 more (4 cohorts), sponsored by Agios Pharmaceuticals. Primary endpoint: Pyruvate kinase activity and thermal stability. Started Dec 2017; status: recruiting.
02
Conditions
hemoglobinopathiessickle cell disease (SCD)beta thalassemiahereditary anemia
Beyond the preview
Go deeper on NL-OMON55777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55777.